Eucrates Biomedical Acquisition Corp. (EUCR) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
250 WEST 55TH STREET, SUITE 13D NEW YORK, NY 10019 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 677 - Blank Checks (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 12/31/2022 | 12/31/2021 | 12/31/2020 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 49,156 | 551,264 | |||
| Cash and cash equivalents | 49,156 | 551,264 | |||
| Prepaid expense | 215,000 | 470,106 | |||
| Total current assets: | 264,156 | 1,021,370 | |||
| Noncurrent Assets | |||||
| Asset, held-in-trust | 104,842,820 | 104,805,536 | |||
| Total noncurrent assets: | 104,842,820 | 104,805,536 | |||
| TOTAL ASSETS: | 105,106,976 | 105,826,906 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 38,460 | ||||
| Accrued liabilities | 38,460 | ||||
| Debt | |||||
| Total current liabilities: | 38,460 | ||||
| Noncurrent Liabilities | |||||
| Other undisclosed noncurrent liabilities | |||||
| Total noncurrent liabilities: | |||||
| Other undisclosed liabilities | 5,761,763 | 10,344,382 | |||
| Total liabilities: | 5,800,223 | 10,344,382 | |||
| Temporary equity, carrying amount | 104,796,260 | 104,796,260 | |||
| Equity | |||||
| Equity, attributable to parent | (5,489,507) | (9,313,736) | |||
| Accumulated deficit | (5,489,507) | (9,313,736) | |||
| Other undisclosed equity | |||||
| Total equity: | (5,489,507) | (9,313,736) | |||
| TOTAL LIABILITIES AND EQUITY: | 105,106,976 | 105,826,906 | |||
Income Statement (P&L) (USD)
| 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|
| Other undisclosed operating loss | (743,071) | |||
| Operating loss: | (743,071) | |||
| Nonoperating income | 4,567,300 | |||
| Investment income, nonoperating | 35,761 | |||
| Income from continuing operations: | 3,824,229 | |||
| Income before gain (loss) on sale of properties: | ✕ | 3,824,229 | ✕ | |
| Net income attributable to parent: | 3,824,229 | |||
| Preferred stock dividends and other adjustments | ||||
| Net income available to common stockholders, diluted: | 3,824,229 | |||
Comprehensive Income (USD)
| 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|
| Net income: | 3,824,229 | |||
| Comprehensive income, net of tax, attributable to parent: | 3,824,229 | |||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.